<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-31T17:43:24Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/36641" metadataPrefix="rdf">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/36641</identifier><datestamp>2026-02-03T11:00:34Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37953</setSpec></header><metadata><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:riuma.uma.es:10630/36641">
      <dc:title>Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS)</dc:title>
      <dc:creator>Robles-Zurita, José Antonio</dc:creator>
      <dc:creator>McMeekin, Nicola</dc:creator>
      <dc:creator>Sullivan, Frank</dc:creator>
      <dc:creator>Mair, Frances S.</dc:creator>
      <dc:creator>Briggs, Andrew</dc:creator>
      <dc:subject>Análisis coste-beneficio</dc:subject>
      <dc:description>Background: Diagnostic blood tests have the potential to identify lung cancer in people&#xd;
at high risk. We assessed the cost-effectiveness of a lung cancer screening intervention, using the&#xd;
EarlyCDT®-Lung Test (ECLS) with subsequent X-ray and low-dose chest CT scans (LDCT) for&#xd;
patients with a positive test result, compared to both usual care and LDCT screening for the target&#xd;
population. Methods: We conducted a model-based lifetime analysis from a UK NHS and personal&#xd;
social services perspective. We estimated incremental net monetary benefit (NMB) for the ECLS&#xd;
intervention compared to no screening and to LDCT screening. Results: The incremental NMB of&#xd;
ECLS intervention compared to no screening was GBP 33,179 (95% CI: −GBP 81,396, GBP 147,180)&#xd;
and GBP 140,609 (95% CI: −GBP 36,255, GBP 316,612), respectively, for a cost-effectiveness threshold&#xd;
of GBP 20,000 and GBP 30,000 per quality-adjusted life year. The same figures compared with LDCT&#xd;
screening were GBP 162,095 (95% CI: GBP 52,698, GBP 271,735) and GBP 52,185 (95% CI: −GBP&#xd;
115,152, GBP 219,711). Conclusions: The ECLS intervention is the most cost-effective screening&#xd;
alternative, with the highest probability of being cost-effective, when compared to no screening or&#xd;
LDCT screening. This result may change with modifications of the parameters, suggesting that the&#xd;
three alternatives considered in the main analysis are potentially cost-effective.</dc:description>
      <dc:date>2025-01-21T11:45:51Z</dc:date>
      <dc:date>2025-01-21T11:45:51Z</dc:date>
      <dc:date>2024-06-18</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS). Curr. Oncol. 2024, 31, 3546–3562. https://doi.org/ 10.3390/curroncol31060261</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10630/36641</dc:identifier>
      <dc:identifier>https://doi.org/ 10.3390/curroncol31060261</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>open access</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>
</metadata></record></GetRecord></OAI-PMH>